Identification
Name(S)-2-((S)-3-ISOBUTYL-2,5-DIOXO-4-QUINOLIN-3-YLMETHYL-[1,4]DIAZEPAN-1YL)-N-METHYL-3-NAPHTALEN-2-YL-PROPIONAMIDE
Accession NumberDB04724
TypeSmall Molecule
GroupsExperimental
DescriptionNot Available
Structure
Thumb
SynonymsNot Available
External IDs Not Available
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
CategoriesNot Available
UNIINot Available
CAS numberNot Available
WeightAverage: 536.6639
Monoisotopic: 536.278741038
Chemical FormulaC33H36N4O3
InChI KeyCOVPLULNDBDXTN-KYJUHHDHSA-N
InChI
InChI=1S/C33H36N4O3/c1-22(2)16-30-33(40)36(29(32(39)34-3)19-23-12-13-25-8-4-5-9-26(25)17-23)15-14-31(38)37(30)21-24-18-27-10-6-7-11-28(27)35-20-24/h4-13,17-18,20,22,29-30H,14-16,19,21H2,1-3H3,(H,34,39)/t29-,30-/m0/s1
IUPAC Name
(2S)-N-methyl-2-[(3S)-3-(2-methylpropyl)-2,5-dioxo-4-(quinolin-3-ylmethyl)-1,4-diazepan-1-yl]-3-(naphthalen-2-yl)propanimidic acid
SMILES
[H][C@@](CC1=CC2=CC=CC=C2C=C1)(N1CCC(=O)N(CC2=CC3=CC=CC=C3N=C2)[C@@]([H])(CC(C)C)C1=O)C(O)=NC
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action
TargetKindPharmacological actionActionsOrganismUniProt ID
Integrin alpha-LProteinunknownNot AvailableHumanP20701 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions Not Available
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials Not Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.00194 mg/mLALOGPS
logP4.35ALOGPS
logP4.67ChemAxon
logS-5.4ALOGPS
pKa (Strongest Acidic)4.79ChemAxon
pKa (Strongest Basic)6.73ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area86.1 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity155.69 m3·mol-1ChemAxon
Polarizability59.52 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9201
Blood Brain Barrier-0.6488
Caco-2 permeable-0.5881
P-glycoprotein substrateSubstrate0.9117
P-glycoprotein inhibitor IInhibitor0.9707
P-glycoprotein inhibitor IIInhibitor0.6791
Renal organic cation transporterNon-inhibitor0.6466
CYP450 2C9 substrateNon-substrate0.8282
CYP450 2D6 substrateNon-substrate0.7505
CYP450 3A4 substrateSubstrate0.8099
CYP450 1A2 substrateNon-inhibitor0.6613
CYP450 2C9 inhibitorNon-inhibitor0.5606
CYP450 2D6 inhibitorNon-inhibitor0.8803
CYP450 2C19 inhibitorNon-inhibitor0.5388
CYP450 3A4 inhibitorNon-inhibitor0.5103
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6748
Ames testNon AMES toxic0.6915
CarcinogenicityNon-carcinogens0.9379
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6660 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8971
hERG inhibition (predictor II)Inhibitor0.6501
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as quinolines and derivatives. These are compounds containing a quinoline moiety, which consists of a benzene ring fused to a pyrimidine ring to form benzo[b]azabenzene.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassQuinolines and derivatives
Sub ClassNot Available
Direct ParentQuinolines and derivatives
Alternative ParentsNaphthalenes / Alpha amino acids and derivatives / 1,4-diazepanes / Pyridines and derivatives / Fatty amides / Tertiary carboxylic acid amides / Heteroaromatic compounds / Secondary carboxylic acid amides / Lactams / Azacyclic compounds
SubstituentsAlpha-amino acid or derivatives / Naphthalene / Quinoline / 1,4-diazepane / Diazepane / Fatty amide / Pyridine / Benzenoid / Fatty acyl / Heteroaromatic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptorsquinolines, monocarboxylic acid amide, naphthalenes, diazepanone (CHEBI:43574 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Metal ion binding
Specific Function:
Integrin alpha-L/beta-2 is a receptor for ICAM1, ICAM2, ICAM3 and ICAM4. It is involved in a variety of immune phenomena including leukocyte-endothelial cell interaction, cytotoxic T-cell mediated killing, and antibody dependent killing by granulocytes and monocytes.
Gene Name:
ITGAL
Uniprot ID:
P20701
Uniprot Name:
Integrin alpha-L
Molecular Weight:
128768.495 Da
Drug created on September 11, 2007 11:49 / Updated on June 11, 2017 20:58